The recent increase in the frequency of endometrial cancer has emphasized the need for accurate diagnosis and improved treatment. The current diagnosis is still based on conventional pathological indicators, such as clinical stage, tumor differentiation, invasion depth and vascular invasion. However, the genetic mechanisms underlying endometrial cancer have gradually been determined, due to developments in molecular biology, leading to the possibility of new methods of diagnosis and treatment planning. New candidate biomarkers for endometrial cancer include those for molecular epigenetic mutations, such as microRNAs. These biomarkers may permit earlier detection of endometrial cancer and prediction of outcomes and are likely to contribute to future personalized therapy for endometrial cancer.
References
[1]
Jemal, A.; Siegel, R.; Xu, J.; Ward, E. Cancer statistics, 2010. CA Cancer J. Clin 2010, 60, 277–300.
[2]
Ushijima, K. Current status of gynecologic cancer in Japan. J. Gynecol. Oncol 2009, 20, 67–71.
[3]
Honda, T.; Urabe, R.; Kurita, T.; Kagami, S.; Kawagoe, T.; Toki, N.; Matsuura, Y.; Hachisuga, T. Trends in the demographic and clinicopathological characteristics in Japanese patients with endometrial cancer, 1990–2010. Int. J. Womens Health 2012, 4, 207–212.
[4]
Bokhman, J.V. Two pathogenetic types of endometrial carcinoma. Gynecol. Oncol 1983, 15, 10–17.
[5]
Deligdisch, L.; Cohen, C.J. Histologic correlates and virulence implications of endometrial carcinoma associated with adenomatous hyperplasia. Cancer 1985, 56, 1452–1455.
[6]
Oehler, M.K.; Brand, A.; Wain, G.V. Molecular genetics and endometrial cancer. J. Br. Menopause Soc 2003, 9, 27–31.
[7]
Bansal, N.; Yendluri, V.; Wenham, R.M. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control 2009, 1, 8–13.
[8]
Gadducci, A.; Cosio, S.; Genazzani, A.R. Tissue and serum biomarkers as prognostic variables in endometrioid-type endometrial cancer. Crit. Rev. Oncol. Hematol 2011, 80, 181–192.
[9]
Doll, A.; Abal, M.; Rigau, M.; Monge, M.; Gonzalez, M.; Demajo, S.; Colás, E.; Llauradó, M.; Alazzouzi, H.; Planagumá, J.; et al. Novel molecular profiles of endometrial cancer-new light through old windows. J. Steroid Biochem. Mol. Biol 2008, 108, 221–229.
[10]
Esteller, M. Dormant hypermethylated tumour suppressor genes: Questions and answers. J. Pathol 2005, 205, 172–180.
[11]
Bhalla, K.N. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J. Clin. Oncol 2005, 23, 3971–3993.
[12]
Krusche, C.A.; Vloet, A.J.; Classen-Linke, I.; von Rango, U.; Beier, H.M.; Alfer, J. Class I histone deacetylase expression in the human cyclic endometrium and endometrial adenocarcinomas. Hum. Reprod 2007, 22, 2956–2966.
[13]
Weichert, W.; Denkert, C.; Noske, A.; Darb-Esfahani, S.; Dietel, M.; Kalloger, S.E.; Huntsam, D.G.; K？bel, M. Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. Neoplasia 2008, 10, 1021–1027.
[14]
Esteller, M.; Levine, R.; Baylin, S.B.; Ellenson, L.H.; Herman, J.G. MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene 1998, 17, 2413–2417.
[15]
Hecht, J.L.; Mutter, G.L. Molecular and pathologic aspects of endometrial carcinogenesis. J. Clin. Oncol 2006, 24, 4783–4791.
Costello, J.F.; Plass, C. Methylation matters. J. Med. Genet 2001, 38, 285–303.
[18]
Di Domenico, M.; Santoro, A.; Ricciardi, C.; Iaccarino, M.; Iaccarino, S.; Freda, M.; Feola, A.; Sanguedolce, F.; Losito, S.; Pasquali, D.; et al. Epigenetic fingerprint in endometrial carcinogenesis: The hypothesis of a uterine field cancerization. Cancer Biol. Ther 2011, 12, 447–457.
[19]
Scolnick, D.M.; Halazonetis, T.D. Chfr defines a mitotic stress checkpoint that delays entry into metaphase. Nature 2000, 27, 430–435.
[20]
Chin, C.F.; Yeong, F.M. Safeguarding entry into mitosis the antephase checkpoint. Mol. Cell Biol 2010, 30, 22–23.
[21]
Yanokura, M.; Banno, K.; Kawaguchi, M.; Hirao, N.; Hirasawa, A.; Susumu, N.; Tsukazaki, K.; Aoki, D. Relationship of aberrant DNA hypermethylation of CHFR with sensitivity to taxanes in endometrial cancer. Oncol. Rep 2007, 17, 41–48.
[22]
Bogen, K.T. Efficient tumorigenesis by mutation-induced failure to terminate microRNA-mediated adaptive hyperplasia. Med. Hypotheses 2013, 80, 83–90.
[23]
Zhi, F.; Wang, S.; Wang, R.; Xia, X.; Yang, Y. From small to big: microRNAs as new players in medulloblastomas. Tumor Biol 2013, 34, 9–15.
[24]
Yanokura, M.; Banno, K.; Kobayashi, Y.; Kisu, I.; Ueki, A.; Ono, A.; Masuda, K.; Nomura, H.; Hirasawa, A.; Susumu, N.; et al. MicroRNA and endometrial cancer: Roles of small RNAs in human tumors and clinical applications. Oncol. Lett 2010, 1, 935–940.
[25]
Devor, E.J.; Hovey, A.M.; Goodheart, M.J.; Ramachandran, S.; Leslie, K.K. microRNA expression profiling of endometrial endometrioid adenocarcinomas and serous adenocarcinomas reveals profiles containing shared, unique and differentiating groups of microRNAs. Oncol. Rep 2011, 26, 995–1002.
[26]
Snowdon, J.; Zhang, X.; Childs, T.; Tron, V.A.; Feilotter, H. The microRNA-200 family is upregulated in endometrial carcinoma. PLoS One 2011, 6, e22828.
[27]
Lee, J.W.; Park, Y.A.; Choi, J.J.; Lee, Y.Y.; Kim, C.J.; Choi, C.; Kim, T.J.; Lee, N.W.; Kim, B.G.; Bae, D.S. The expression of the miRNA-200 family in endometrial endometrioid carcinoma. Gynecol. Oncol 2011, 120, 56–62.
[28]
Torres, A.; Torres, K.; Pesci, A.; Ceccaroni, M.; Paszkowski, T.; Cassandrini, P.; Zamboni, G.; Maciejewski, R. Diagnostic and prognostic significance of miRNA signatures in tissues and plasma of endometrioid endometrial carcinoma patients. Int. J. Cancer 2013, 132, 1633–1645.
[29]
Ramón, L.A.; Braza-Bo？ls, A.; Gilabert, J.; Chirivella, M.; Espa？a, F.; Estellés, A.; Gilabert-Estellés, J. microRNAs related to angiogenesis are dysregulated in endometrioid endometrial cancer. Hum. Reprod 2012, 27, 3036–3045.
[30]
Hiroki, E.; Suzuki, F.; Akahira, J.; Nagase, S.; Ito, K.; Sugawara, J.; Miki, Y.; Suzuki, T.; Sasano, H.; Yaegashi, N. MicroRNA-34b functions as a potential tumor suppressor in endometrial serous adenocarcinoma. Int J. Cancer 2012, 131, E395–404.
[31]
Tsuruta, T.; Kozaki, K.; Uesugi, A.; Furuta, M.; Hirasawa, A.; Imoto, I.; Susumu, N.; Aoki, D.; Inazawa, J. miR-152 is a tumor suppressor microRNA that is silenced by DNA hypermethylation in endometrial cancer. Cancer Res 2011, 71, 6450–6462.
[32]
Ketabi, Z.; Mosgaard, B.J.; Gerdes, A.M.; Ladelund, S.; Bernstein, I.T. Awareness of endometrial cancer risk and compliance with screening in hereditary nonpolyposis colorectal cancer. Obstet. Gynecol 2012, 120, 1005–1012.
[33]
Kalady, M.F.; Lipman, J.; McGannon, E.; Church, J.M. Risk of colonic neoplasia after proctectomy for rectal cancer in hereditary nonpolyposis colorectal cancer. Ann. Surg 2012, 255, 1121–1125.
[34]
Banno, K.; Yanokura, M.; Kobayashi, Y.; Kawaguchi, M.; Nomura, H.; Hirasawa, A.; Susumu, N.; Aoki, D. Endometrial cancer as a familial tumor: Pathology and molecular carcinogenesis (review). Curr. Genomics 2009, 10, 127–132.
[35]
Banno, K.; Susumu, N.; Hirao, T.; Yanokura, M.; Hirasawa, A.; Aoki, D.; Udagawa, Y.; Sugano, K.; Nozawa, S. Two Japanese kindreds occurring endometrial cancer meeting new clinical criteria for hereditary non-polyposis colorectal cancer (HNPCC), Amsterdam Criteria II. J. Obstet. Gynaecol. Res 2004, 30, 287–292.
[36]
Hirai, Y.; Banno, K.; Suzuki, M.; Ichikawa, Y.; Udagawa, Y.; Sugano, K.; Miki, Y. Molecular epidemiological and mutational analysis of DNA mismatch repair (MMR) genes in endometrial cancer patients with HNPCC-associated familial predisposition to cancer. Cancer Sci 2008, 99, 1715–1719.
[37]
Banno, K.; Kisu, I.; Yanokura, M.; Tsuji, K.; Masuda, K.; Ueki, A.; Kobayashi, Y.; Yamagami, W.; Nomura, H.; Tominaga, E.; et al. Epimutation and cancer: A new carcinogenic mechanism of Lynch syndrome. Int. J. Oncol 2012, 41, 793–797.
[38]
Gazzoli, I.; Loda, M.; Garber, J.; Syngal, S.; Kolodner, R.D. A hereditary nonpolyposis colorectal carcinoma case associated with hypermethylation of the MLH1 gene in normal tissue and loss of heterozygosity of the unmethylated allele in the resulting microsatellite instability-high tumor. Cancer Res 2002, 62, 3925–3928.
[39]
Ligtenberg, M.J.; Kuiper, R.P.; Chan, T.L.; Goossens, M.; Hebeda, K.M.; Voorendt, M.; Lee, T.Y.; Bodmer, D.; Hoenselaar, E.; Hendriks-Cornelissen, S.J.; et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1. Nat. Genet 2009, 41, 12–17.
[40]
Nelen, M.R.; Kremer, H.; Konings, I.B.; Schoute, F.; van Essen, A.J.; Koch, R.; Woods, C.G.; Fryns, J.P.; Hamel, B.; Hoefsloot, L.H.; et al. Novel PTEN mutations in patients with Cowden disease: Absence of clear genotype-phenotype correlations. Eur. J. Hum. Genet 1999, 7, 267–273.
[41]
Nelen, M.R.; Padberg, G.W.; Peeters, E.A.; Lin, A.Y.; van den Helm, B.; Frants, R.R.; Coulon, V.; Goldstein, A.M.; van Reen, M.M.; Easton, D.F.; et al. Localization of the gene for Cowden disease to chromosome 10q22–23. Nat. Genet 1996, 13, 114–116.
[42]
Liaw, D.; Marsh, D.J.; Li, J.; Dahia, P.L.; Wang, S.I.; Zheng, Z.; Bose, S.; Call, K.M.; Tsou, H.C.; Peacocke, M.; et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat. Genet 1997, 16, 64–67.
[43]
Salem, O.S.; Steck, W.D. Cowden’s disease (multiple hamartoma and neoplasia syndrome). A case report and review of the English literature. J. Am. Acad. Dermatol 1983, 8, 686–696.
[44]
Higuchi, M.; Onishi, K.; Kikuchi, C.; Gotoh, Y. Scaffolding function of PAK in the PDK1-Akt pathway. Nat. Cell. Biol 2008, 10, 1356–1364.
[45]
Beggs, A.D.; Latchford, A.R.; Vasen, H.F.; Moslein, G.; Alonso, A.; Aretz, S.; Bertario, L.; Blanco, I.; Bulow, S.; Burn, J.; et al. Peutz-Jeghers syndrome: A systematic review and recommendations for management. Gut 2010, 59, 975–986.
[46]
Scully, R.E. Sex cord tumor with annular tubules a distinctive ovarian tumor of the Peutz-Jeghers syndrome. Cancer 1970, 25, 1107–1121.
[47]
Giardiello, F.M.; Brensinger, J.D.; Tersmette, A.C.; Goodman, S.N.; Petersen, G.M.; Booker, S.V.; Cruz-Correa, M.; Offerhaus, J.A. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000, 119, 1447–1453.
[48]
Banno, K.; Kisu, I.; Yanokura, M.; Tsuji, K.; Masuda, K.; Ueki, A.; Kobayashi, Y.; Yamagami, W.; Nomura, H.; Tominaga, E.; et al. Biomarkers in endometrial cancer: Possible clinical applications. Oncol. Lett 2012, 3, 1175–1180.
[49]
Lee, E.J.; Kim, T.J.; Kim, D.S.; Choi, C.H.; Lee, J.W.; Lee, J.H.; Bae, D.S.; Kim, B.G. p53 alteration independently predicts poor outcomes in patients with endometrial cancer: A clinicopathologic study of 131 cases and literature review. Gynecol. Oncol 2010, 116, 533–538.
[50]
Risinger, J.I.; Hayes, K.; Maxwell, G.L.; Carney, M.E.; Dodge, R.K.; Barrett, J.C.; Berchuck, A. PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin. Cancer Res 1998, 4, 3005–3010.
[51]
Mackay, H.J.; Gallinger, S.; Tsao, M.S.; McLachlin, C.M.; Tu, D.; Keiser, K.; Eisenhauer, E.A.; Oza, A.M. Prognostic value of microsatellite instability (MSI) and PTEN expression in women with endometrial cancer: Results from studies of the NCIC Clinical Trials Group (NCIC CTG). Eur. J. Cancer 2010, 46, 1365–1373.
[52]
Saegusa, M.; Hashimura, M.; Yoshida, T.; Okayasu, I. Beta-catenin mutations and aberrant nuclear expression during endometrial tumorigenesis. Br. J. Cancer 2001, 84, 209–217.
[53]
Mizuuchi, H.; Nasim, S.; Kudo, R.; Silverberg, S.G.; Greenhouse, S.; Garrett, C.T. Clinical implications of K-ras mutations in malignant epithelial tumors of the endometrium. Cancer Res 1992, 52, 2777–2781.
[54]
Jo, H.; Kim, J.W.; Kang, G.H.; Park, N.H.; Song, Y.S.; Kang, S.B.; Lee, H.P. Association of promoter hypermethylation of the RASSF1A gene with prognostic parameters in endometrial cancer. Oncol. Res 2006, 16, 205–209.
[55]
Mizumoto, Y.; Kyo, S.; Mori, N.; Sakaguchi, J.; Ohno, S.; Maida, Y.; Hashimoto, M.; Takakura, M.; Inoue, M. Activation of ERK1/2 occurs independently of KRAS or BRAF status in endometrial cancer and is associated with favorable prognosis. Cancer Sci 2007, 98, 652–658.
Zaino, R.J.; Davis, A.T.; Ohlsson-Wilhelm, B.M.; Brunetto, V.L. DNA content is an independent prognostic indicator in endometrial adenocarcinoma. A Gynecologic Oncology Group study. Int. J. Gynecol. Pathol 1998, 17, 312–319.
[58]
Scambia, G.; Gadducci, A.; Panici, P.B.; Foti, E.; Ferdeghini, M.; Ferrandina, G.; Amoroso, M.; Castellani, C.; Facchini, V.; Mancuso, S. Combined use of CA 125 and CA 15–3 in patients with endometrial carcinoma. Gynecol. Oncol 1994, 54, 292–297.
[59]
Sood, A.K.; Buller, R.E.; Burger, R.A.; Dawson, J.D.; Sorosky, J.I.; Berman, M. Value of preoperative CA 125 level in the management of uterine cancer and prediction of clinical outcome. Obstet. Gynecol 1997, 90, 441–447.
[60]
Diefenbach, C.S.; Shah, Z.; Iasonos, A.; Barakat, R.R.; Levine, D.A.; Aghajanian, C.; Sabbatini, P.; Hensley, M.L.; Konner, J.; Tew, W.; et al. Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer. Gynecol. Oncol 2007, 104, 435–442.
[61]
Moore, R.G.; Brown, A.K.; Miller, M.C.; Badgwell, D.; Lu, Z.; Allard, W.J.; Granai, C.O.; Bast, R.C., Jr; Lu, K. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol. Oncol 2008, 110, 196–201.
[62]
Mutz-Dehbalaie, I.; Egle, D.; Fessler, S.; Hubalek, M.; Fiegl, H.; Marth, C.; Widschwendter, A. HE4 is an independent prognostic marker in endometrial cancer patients. Gynecol. Oncol 2012, 126, 186–191.
